News from the centers

04.03.2016

Publication about novel non-steroidal MR antagonism (AG Kintscher)

Back to Overview

You are here:

Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-Induced Cardiac Hypertrophy.

Grune J, Benz V, Brix S, Salatzki J, Blumrich A, Höft B, Klopfleisch R, Foryst-Ludwig A, Kolkhof P, Kintscher U.

Pharmacological blockade of mineralocorticoid receptors (MR) is known as an efficacious therapy in chronic heart failure. Therapy with steroidal MR antagonists such as spironolactone or
eplerenone (EPL) is often limited because of side effects. Recently, a new highly selective and potent, nonsteroidal MR antagonist, finerenone (FIN), has been developed.

This study shows beneficial effects of nonsteroidal MR antagonism by FIN on left ventricular mass development in pressure overload associated with a distinct cardiac gene expression profile.

http://www.ncbi.nlm.nih.gov/pubmed/26859196

Contact

M.D., Professor of Pharmacology Ulrich Kintscher

Director of CCRCharitéUniversitätsmedizin Berlin
Hessische Str. 3-4
10115 Berlin

Postal address:Hessische Str. 3-410115 Berlin

Directions / Location map
Dr. rer. nat. Jana Grune

Research assistantCharitéUniversitätsmedizin BerlinBerlin

Postal address:Berlin



Back to Overview